Volume 110 Issue 6, December 2024

Research Article

Read the latest issue. It contains the following articles: Hot topics in genitourinary_cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy.
Proton therapy for pediatric malignancies: Indications and challenges focusing on the oncological landscape
Enhanced patient journey associated with improved overall survival in colon cancer patients: A study by the Ligurian Oncology Network
Practices and views about palliative care at the end of life: A survey of oncologists from the Italian region of Liguria
Effect of body mass index on immune checkpoint inhibitor efficacy in patients with advanced cancer
Self-perceived attitudes of Italian oncology nurses towards clinical trial involvement: A cohort observational study.
Fat necrosis after accelerated partial breast irradiation or hypofractionated whole breast irradiation: A case-control study.
High throughput sequencing reveals alterations in B cell receptor repertoires associated with the progression of hepatic cirrhosis to hepatocellular carcinoma
Preoperative chemo-CIRT in Re/BRe pancreatic cancer: Insights from a multicenter prospective phase lI clinical study_(NCT03822936)
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome
Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making

Time trends of cancer incidence in young adults (20-49 years) in Italy. A population – based study, 2008-2017

Research Article

To evaluate short-term (2008–2017) cancer incidence trends in Italy for individuals aged 20-49 years by sex and cancer type. Observational study from population-based data collected by 20 Italian Cancer Registries, covering 33% of the Italian population. The age-standardized incidence rates (ASRs), overall and stratified by area, sex, cancer site or type, and major age groups (i.e., 20-39, 40-49), were computed.

KRAS inhibitors in drug resistance and potential for combination therapy

Review Article

Kirsten Rat Sarcoma (KRAS) is a potent target for cancer therapy because it acts as a signaling hub, engaging in various signaling pathways and regulating a number of cellular functions like cell differentiation, proliferation, and survival. Recently, an emergency approval from the US-FDA has been issued for KRASG12C inhibitors (sotorasib and adagrasib) for metastatic lung cancer treatment.